Search Clinical Trials
Before medications are approved by the U.S. Food and Drug Administration (FDA) or before certain therapy methods are widely accepted as effective, they are tested on people who volunteer to participate in a clinical trial.
Organizations across the country are looking for people like you to take part in their research studies. The list of studies below have been selected from ClinicalTrials.gov based on their inclusion of one or more of the following terms: anxiety disorders, depression, OCD, PTSD, and bipolar disorder.
The Anxiety and Depression Association of America (ADAA) is supportive of research that is conducted through clinical trials. Participating in research can potentially help change the mental health outcomes for you and others who suffer anxiety, depression, and related disorders. You may learn about new interventions/treatments that are being considered.
Read this ADAA blog about things to know and questions to ask before committing to a clinical trial.
This website page is brought to you in partnership with ResearchMatch.
Sponsor Condition of Interest |
---|
Gut Microbiome and Depression
Washington University School of Medicine
Multiple Sclerosis
Depression
The purpose of this project is to determine if specific gut microbiome or gut-derived
metabolites are associated with depression in patients with Multiple Sclerosis (pwMS).
Mechanistically, the investigators further hypothesize that depression in pwMS is related
to decreased abundance of gut bacteria... expand
The purpose of this project is to determine if specific gut microbiome or gut-derived metabolites are associated with depression in patients with Multiple Sclerosis (pwMS). Mechanistically, the investigators further hypothesize that depression in pwMS is related to decreased abundance of gut bacteria with GABA-producing activities and/or with anti-inflammatory properties. To determine if the presence of depression in pwMS is associated with specific gut microbiome, gut-derived metabolites or peripheral blood immune profiles. The investigators will perform a cross-sectional study in clinically stable pwMS recruited at the John L. Trotter MS Center. The investigators will evaluate the presence of depression using the Quality of Life in Neurological Disorders (Neuro-Qol) depression scale, one of the 13 scales in the Neuro-Qol recently developed by the NIH using modern psychometric techniques and validated in pwMS. A total of 120 pwMS will be recruited: 60 with and 60 without depression based on the Neuro-Qol depression scale. At the study visit each participant will be asked to provide a stool sample for microbiome analyses and a blood sample for peripheral blood immunophenotyping. Potential confounders will be collected and treated as covariates in the analyses. These include: 1) degree of disability (EDSS); 2) treatment with anti-depressants and DMTs; 3) a 4-days food diary to evaluate diet composition; 4) weight and height to calculate the BMI; 5) fatigue; 6) level of physical activity; 7) sleep quality. Type: Observational Start Date: Jan 2022 |
Clinical Validation of Samsung Smartwatch
Massachusetts General Hospital
Major Depressive Disorder
Mood Disorders
Mental Health Issue
Objective:
Wearable technology holds promising potential for mental health monitoring and detection.
Samsung has developed an algorithm that they believe can detect signs of depression and
anxiety in smartwatch users. They have used this algorithm to create a "Mindfulness
Index," which is an easily... expand
Objective: Wearable technology holds promising potential for mental health monitoring and detection. Samsung has developed an algorithm that they believe can detect signs of depression and anxiety in smartwatch users. They have used this algorithm to create a "Mindfulness Index," which is an easily understood visual index of mental health. The primary aim of the study is to evaluate the performance of Samsung's Mindfulness Index in identifying those who have received a diagnosis of Major Depressive Disorder (MDD) from a clinician-administered semi-structured diagnostic interview. Research Procedures: The target sample size is 75 individuals diagnosed with current Major Depressive Disorder and 75 healthy controls. To meet this target, the recruitment target is set at 215 participants. Participants will be assigned to the MDD condition, or the healthy control condition based on their score on the Beck Depression Inventory. Each subject will be followed for 3 months. Participants will be provided with a Samsung smartphone and Samsung smartwatch. Participants will be asked to wear the smartwatch 24 hours per day, except while charging. This smartwatch will collect data on heartrate, sleep time, and step count. During the study, each day participants will receive texts prompting a link to a "daily diary." These surveys will ask about depression and anxiety symptoms. Additionally, during the first 3 weeks of the study, participants will participate in ecological momentary assessment; texts will be sent 5 times per day prompting participants to fill out a survey about how they currently feel in that moment. These extra surveys will stop after the first 3 weeks of the study, but the daily diary surveys will continue throughout the study. Furthermore, virtual clinician visits will occur at weeks 4, 8, and 12. Type: Observational Start Date: Mar 2023 |
Tracking Response to Antidepressants in Advance of Investigational Trials
Adams Clinical
Major Depressive Disorder
TRAIT is an open-label observational study to evaluate treatment response to
selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake
inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD)
and seeking enrollment in investigational trials. expand
TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials. Type: Observational Start Date: Jan 2019 |
Circadian Influence on Prolonged Exposure Therapy for PTSD
Massachusetts General Hospital
PTSD
Proposed research will examine time-of-day effects on trauma-related fear extinction
using Prolonged Exposure Therapy (PE) telemedicine for Posttraumatic Stress Disorder
(PTSD) in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure
will be change in psychophysiological reactivity... expand
Proposed research will examine time-of-day effects on trauma-related fear extinction using Prolonged Exposure Therapy (PE) telemedicine for Posttraumatic Stress Disorder (PTSD) in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure will be change in psychophysiological reactivity to script-driven imagery (SDI-PR) measured, in person, at pre-treatment, after 5 PE sessions (mid-treatment), and after all 10 PE sessions (post-treatment). A secondary mechanistic outcome will be session-to-session reduction in peak subjective units of distress (SUDS) ratings to imaginal exposures. The primary clinical outcome will be change in Clinican Administered PTSD Scale (CAPS-5) severity score; a secondary clinical outcome will be session-to-session reduction in self-reported PTSD symptoms using the PTSD checklist (PCL-5). Participants meeting inclusion criteria (described below) will be randomized to either PE sessions that begin from 07:00 to a time no later than 2 hours past a participant's customary rise time, or to the last treatment session of the day beginning at 16:00 or later (26 per arm). Participants will complete daily at-home imaginal-exposure homework within the same time frame as their PE sessions are scheduled, i.e., within 2 hours of awakening for morning (AM) group and between 16:00 and 2 hours before bedtime for late afternoon (PM) group. Type: Interventional Start Date: Jul 2022 |
Microbiome, Anxiety and Cognitive Orientation Study
Endominance
Anxiety
Microbiome
Mood Disorders
Neurodegeneration
Depression
Mounting evidence shows that the gut microbiome plays an important role in communication
within the gut-brain axis. However, the relationship between gut microbiota and their
influence on anxiety is still not fully understood. Recent studies on mice found a
specific microbe-produced molecule, 4-ethylphenyl... expand
Mounting evidence shows that the gut microbiome plays an important role in communication within the gut-brain axis. However, the relationship between gut microbiota and their influence on anxiety is still not fully understood. Recent studies on mice found a specific microbe-produced molecule, 4-ethylphenyl sulfate (4EPS), can induce anxious behavior. 4EPS is produced by gut microbes in mice and humans. Research suggests higher 4EPS levels may strongly be associated with anxiety levels. However, anxiety is far more complicated than changes in a single molecule. There are many more factors to consider when it comes to anxiety, including various aspects of one's lifestyle and how humans perceive their environment (cognitive orientation). The primary research goal is to better understand the effects 4EPS has on human anxiety behavior and the role cognitive orientation has in connection to anxiety. Type: Observational Start Date: Jun 2022 |
The BIomarker Guided Study for Depression
Stanford University
Major Depressive Disorder
The diagnosis of major depression relies on patient reports, and two patients with the
same diagnosis might share only one symptom. Thus, a single mechanism is unlikely to
underlie a broad descriptive diagnosis such as major depression. Our approach is anchored
by a neural circuit taxonomy that proposes... expand
The diagnosis of major depression relies on patient reports, and two patients with the same diagnosis might share only one symptom. Thus, a single mechanism is unlikely to underlie a broad descriptive diagnosis such as major depression. Our approach is anchored by a neural circuit taxonomy that proposes distinct biotypes of depression derived from functional magnetic resonance imaging (fMRI) (Williams et al., 2016). In this study, we aim to target a putative type of major depression that arises from dysfunction in cognitive control neural circuitry with a drug called guanfacine. Type: Interventional Start Date: Jul 2022 |
Near Infrared Spectroscopy (NIRS) for Assessment of Depression
University of California, San Francisco
Major Depressive Disorder
Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and
reliably distinguishes the symptoms and severity of depression, with the help of repeated
measure (up to five visits per subject) comparison of patients being treated for Major
Depressive Disorder with control,... expand
Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and reliably distinguishes the symptoms and severity of depression, with the help of repeated measure (up to five visits per subject) comparison of patients being treated for Major Depressive Disorder with control, non-depressed subjects. Type: Interventional Start Date: Jan 2019 |
Fresh RX: NHS 2020
Washington University School of Medicine
Premature Birth
Birth Weight
Post Partum Depression
Health Care Utilization
Nutrition Deficiency Due to Insufficient Food
This study is an evaluation of the Fresh Rx: Nourishing Healthy Starts program
administered by Operation Food Search, a St. Louis-based nonprofit organization. The
program provides food and nutrition supports to food insecure pregnant women in
conjunction with integrative care services in order to... expand
This study is an evaluation of the Fresh Rx: Nourishing Healthy Starts program administered by Operation Food Search, a St. Louis-based nonprofit organization. The program provides food and nutrition supports to food insecure pregnant women in conjunction with integrative care services in order to improve health and birth outcomes for both the mother and the child. The purpose of this study is to test the efficacy of this approach through a field experiment, and to assess the extent to which these services can provide cost savings to the healthcare system. Type: Interventional Start Date: Aug 2021 |
Interpretation Training to Reduce Anxiety: Evaluating Technology-based Delivery Models and Methods to...
University of Virginia
Anxiety
The project aims to compare effectiveness and target engagement of CBM-I delivered via
computer vs. mobile phone, and test if adding minimal human contact for participants at
risk of dropout improves retention and outcomes. expand
The project aims to compare effectiveness and target engagement of CBM-I delivered via computer vs. mobile phone, and test if adding minimal human contact for participants at risk of dropout improves retention and outcomes. Type: Interventional Start Date: Jan 2019 |
Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
University of California, San Francisco
Opioid Toxicity
Pupillary Miosis
Respiratory Depression
This study will establish the relationship between magnitude of opioid exposure and a
pupillary measure referred to as PUAL (pupillary unrest in ambient light), in subjects
aged 40-60. Previous investigation demonstrated that loss of PUAL was a sensitive,
discriminative indicator of opioid toxicity... expand
This study will establish the relationship between magnitude of opioid exposure and a pupillary measure referred to as PUAL (pupillary unrest in ambient light), in subjects aged 40-60. Previous investigation demonstrated that loss of PUAL was a sensitive, discriminative indicator of opioid toxicity and respiratory depression among subjects aged 20-40 years old. Population data indicate that pupil size and PUAL decline slightly with age. The investigators will explore whether PUAL proves to be a sensitive indicator of opioid exposure and respiratory depression in this older group. Type: Interventional Start Date: Oct 2022 |
IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)
Michigan State University
Major Depressive Disorder
This study tests the efficacy of interpersonal psychotherapy (IPT) for major depression
following perinatal loss (early and late fetal death and early neonatal death) in a
sample of 274 women in Flint and Detroit, Michigan. The trial will be the first fully
powered randomized trial of treatment for... expand
This study tests the efficacy of interpersonal psychotherapy (IPT) for major depression following perinatal loss (early and late fetal death and early neonatal death) in a sample of 274 women in Flint and Detroit, Michigan. The trial will be the first fully powered randomized trial of treatment for any psychiatric disorder following perinatal loss. Type: Interventional Start Date: Aug 2021 |
Translational Research Center for TBI and Stress Disorders: Virtual Assessment of Deployment Trauma and...
VA Boston Healthcare System
TBI (Traumatic Brain Injury)
PTSD
For this clinical demonstration study, Veterans will be assessed with a battery of
questionnaires/surveys and a 1:1 clinical interview with a V-TRACTS psychologist to
target domains of head injury, psychological trauma, depression, suicidality, anxiety,
chronic pain and sleep, substance use and activity... expand
For this clinical demonstration study, Veterans will be assessed with a battery of questionnaires/surveys and a 1:1 clinical interview with a V-TRACTS psychologist to target domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. V-TRACTS will convene a weekly consensus meeting to evaluate all the data, and develop a recommendation plan. After the consensus meeting, a V-TRACTS psychologist will provide comprehensive feedback encompassing the entire assessment battery. Additionally, if warranted, the investigators will offer an optional cognitive assessment, as well as rehabilitation options that the consensus committee targets the individual Veteran's needs and also via VA telehealth or other approved online service. It will be the Veteran's choice whether he/she wants to participate in any one or more of these options. Type: Observational [Patient Registry] Start Date: Dec 2020 |
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants...
Janssen Research & Development, LLC
Depressive Disorder, Major
Anhedonia
The purpose of this study is to assess how well aticaprant works compared to placebo when
given in addition to antidepressant therapy (selective serotonin reuptake inhibitor
[SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) in preventing return of
depression symptoms in participants with... expand
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant. Type: Interventional Start Date: Sep 2024 |
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc.
Major Depressive Disorder
The goal of this clinical trial is to learn if ABX-002 added to an existing
antidepressant treatment will benefit depression symptoms in adults with moderate to
severe major depressive disorder who have had an inadequate response to their
antidepressant.
This is a double-blind, placebo-controlled,... expand
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, Eligibility evaluation and 1:1 Randomization to ABX-002 vs. Placebo control (Baseline - Day 1); approximately 35 days 2. 42-day Treatment Period 3. 2-week post dose Safety Follow-up Period Type: Interventional Start Date: Sep 2024 |
Cognitive Control Training for Extinction in PTSD
VA Office of Research and Development
Post-Traumatic Stress Disorders
Stress Disorders, Traumatic
Post Traumatic Stress Disorder
PTSD
Trauma and Stressor Related Disorders
The proposed study will test whether a working memory training (WMT) program improves
fear extinction learning and its underlying neural circuitry in Veterans with
posttraumatic stress disorder (PTSD). WMT is designed to improves the ability to maintain
task-relevant information in mind. The project... expand
The proposed study will test whether a working memory training (WMT) program improves fear extinction learning and its underlying neural circuitry in Veterans with posttraumatic stress disorder (PTSD). WMT is designed to improves the ability to maintain task-relevant information in mind. The project will further validate the relationship between working memory and fear extinction using novel computational and multivariate analyses that link to specific PTSD symptoms. If WMT can enhance fear extinction learning, then WMT may be a powerful adjunctive treatment that can enhance exposure therapy outcomes or be leveraged as a stand-alone treatment. This project supports the Department of Veteran Affairs mission of developing viable targets of treatment for Veterans with PTSD. Type: Interventional Start Date: Oct 2024 |
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder...
Janssen Research & Development, LLC
Depressive Disorder, Major
Anhedonia
The purpose of this study is to evaluate how well aticaprant works as compared with
placebo when given along with an antidepressant therapy in improving the depressive
symptoms in adult participants with major depressive disorder (MDD) with moderate to
severe anhedonia (ANH+) who have not responded... expand
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have not responded well to current antidepressant therapy with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI). Type: Interventional Start Date: Jun 2024 |
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants...
AbbVie
Bipolar I Disorder
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with
significant morbidity and mortality defined by episodes of mania and depression (or
symptoms of both at once, known as mixed features). This prospective, observational study
will examine effectiveness, functioning and... expand
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with significant morbidity and mortality defined by episodes of mania and depression (or symptoms of both at once, known as mixed features). This prospective, observational study will examine effectiveness, functioning and quality of life outcomes in adult patients with BP-I experiencing a major depressive episode (with or without mixed features) requiring treatment and initiating treatment with cariprazine. It will examine outcomes of cariprazine treatment in a real-world setting in patients with BP-I commonly seen in clinical practices. Cariprazine (Vraylar) is a medication indicated in the United States and Canada to treat adult patients experiencing manic, mixed or depressive episodes associated with BP-I. This study plans to enroll approximately 170 adult patients with BP-I from the United States and Canada. Cariprazine should be prescribed by the physician under the usual and customary practice of physician prescription. The decision to initiate treatment with cariprazine should be made prior to, and independently from, the patient's decision to participate in the study. Participants will receive cariprazine as prescribed by their physician. Observational data will be collected during visits which should align to routine standard of care for a duration of up to 24 weeks. Type: Observational Start Date: Apr 2024 |
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to...
Janssen Research & Development, LLC
Depressive Disorder, Major
The purpose of this study is to assess the socio-demographic, disease-related and
treatment-related characteristics, and the standard of care (SOC) treatment patterns of
participants with major depressive disorder (MDD) with anhedonia with inadequate response
to their current antidepressant treatments... expand
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment. Type: Observational Start Date: Apr 2023 |
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
Rush University Medical Center
PTSD
Chronic Pain
Although most people recover from acute pain (such as pain caused by injury, surgery,
repetitive motion, or unknown causes), many people do not fully recover and will
experience chronic pain. Untreated posttraumatic stress disorder (PTSD) appears to be a
key risk factor for the transition from acute... expand
Although most people recover from acute pain (such as pain caused by injury, surgery, repetitive motion, or unknown causes), many people do not fully recover and will experience chronic pain. Untreated posttraumatic stress disorder (PTSD) appears to be a key risk factor for the transition from acute pain to chronic pain. However, few published studies have addressed the issue of preventing the transition from acute to chronic pain via PTSD reduction. This project will aim to test whether trauma-related PTSD symptoms can be reduced using either Stellate Ganglion Block (SGB) treatment or Cognitive Processing Therapy (CPT), and whether reducing PTSD symptoms can prevent the transition from non-injury based acute pain to chronic pain. Type: Interventional Start Date: Sep 2023 |
Digital Single Session Intervention for Youth Mental Health
Harvard University
Anxiety
Depression
Conduct Disorder
Stress
The aim of this study is to test the effectiveness of a single-session, digital
intervention teaching the principle of practicing the opposite, when administered to
youths on the waitlist for psychotherapy, with usual waitlist procedures as a control
condition. expand
The aim of this study is to test the effectiveness of a single-session, digital intervention teaching the principle of practicing the opposite, when administered to youths on the waitlist for psychotherapy, with usual waitlist procedures as a control condition. Type: Interventional Start Date: Sep 2022 |
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
University of Pennsylvania
OCD
Studies show that hormones affect the brain's fear extinction network, which is relevant
for therapy involving exposure and response prevention (EX/RP), a first-line treatment
for obsessive compulsive disorder (OCD). This study will examine the effect of delivering
EX/RP to women during different... expand
Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms. Type: Interventional Start Date: Jun 2022 |
Study to Evaluate Weight Gain As Assessed by Change in BMI Z-score in Pediatric Subjects with Schizophrenia...
Alkermes, Inc.
Schizophrenia
Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs
olanzapine expand
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine Type: Interventional Start Date: Jun 2022 |
Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
VA Office of Research and Development
Schizophrenia
Schizoaffective
Bipolar Disorder 1
This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an
adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The
two-arm randomized controlled trial will compare the efficacy of YE compared to the
Wellness Lifestyle Program (WLP). Primary... expand
This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The two-arm randomized controlled trial will compare the efficacy of YE compared to the Wellness Lifestyle Program (WLP). Primary outcomes of the study will be self-report and performance-based measures of community functioning, defined in the investigators study as social, leisure, employment, and life skills functioning in the community. Secondary outcomes will include cognition and physical fitness measures. Type: Interventional Start Date: Oct 2022 |
Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers,...
University of Washington
Depression
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
This study compares the effectiveness of technology-enhanced collaborative care
management (t-CoCM) to usual collaborative care management (u-CoCM) in achieving fidelity
to processes of care and reducing depression symptoms in patients currently receiving
cancer treatment. CoCM is a population-based,... expand
This study compares the effectiveness of technology-enhanced collaborative care management (t-CoCM) to usual collaborative care management (u-CoCM) in achieving fidelity to processes of care and reducing depression symptoms in patients currently receiving cancer treatment. CoCM is a population-based, integrated care approach, where care managers, who are clinicians (typically clinical social workers), deliver behavioral treatments, coordinate psychosocial care, monitor outcomes, and adjust treatment with the input of a psychiatric consultant. The use of t-CoCM may improve the treatment of depression and improve patient outcomes and quality of life. Type: Interventional Start Date: Apr 2022 |
Behavioral Activation Teletherapy to Increase Physical Activity
University of Texas Southwestern Medical Center
Depression
Depressive Disorder
Depressive Symptoms
Depressive Episode
This is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief,
10-session Behavioral Activation intervention delivered via teletherapy to increase
physical activity and treat depressive symptoms. expand
This is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief, 10-session Behavioral Activation intervention delivered via teletherapy to increase physical activity and treat depressive symptoms. Type: Interventional Start Date: Aug 2021 |
- Previous
- Next